Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

A 12-YEAR-OLD boy has been left blind because he would only eat burgers and doughnuts. The unnamed child who lived in the US ...

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease. iView Therapeutics completes enrollment in phase 1/2 trial for ...

Meibomian gland dysfunction assessments in children a highlight at the Tear Film & Ocular Surface Society's 2024 meeting.

What is macular degeneration? There is a structure called the retina in the back of our eyes that acts like film, capturing images that go to our brains for interpretation. The retina is vulnerable to ...

Science Corporation, a biotech startup launched by a Neuralink cofounder who left the company, claims that's achieved a ...

S cience Corporation, a rival to Elon Musk’s Neuralink in the development of brain-computer interface (BCI) technology, has just unveiled promising early clinical trial results for an eye implant that ...

LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - ...